These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7232826)

  • 81. Improvement of efficacy of antitumor agents by conagenin.
    Kawatsu M; Yamashita T; Ishizuka M; Takeuchi T
    J Antibiot (Tokyo); 1995 Mar; 48(3):222-5. PubMed ID: 7730156
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Synthesis of 5'-thymidinyl bis(1-aziridinyl)phosphinates as antineoplastic agents.
    Hsiao LY; Bardos TJ
    J Med Chem; 1981 Jul; 24(7):887-9. PubMed ID: 7277400
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Influence of the immunomodulating compound BM 12.531 (azimexone) on radioresistance and granulopoietic colony forming units in mice.
    Gassel WD; Laukel H; Braun R; Werner T; Bicker U
    Exp Pathol; 1981; 20(2):105-7. PubMed ID: 7327218
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparative studies on the antitumor effect on intravenous administration of carbazilquinone and mitomycin-C.
    Okada N; Arakawa M
    Gan; 1976 Dec; 67(6):805-12. PubMed ID: 1021507
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y.
    Schmid FA; Hutchison DJ
    Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791
    [No Abstract]   [Full Text] [Related]  

  • 86. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
    Nitta K; Tanaka T; Takeuchi M
    Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Phase II trial of diaziquone in patients with colon cancer.
    Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
    Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Prevention and therapy of L1210 leukemia in mice, using inactivated and grafted tumor cells, in association with the immunomodulator P40, and Antineoplastic Agents (author's transl)].
    Relyveld EH; Bizzini B; Ben-Efraim S
    C R Seances Acad Sci III; 1982 Mar; 294(12):571-6. PubMed ID: 6809234
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Use of hexaphosphamide for the treatment of myelocytic leukemia].
    Nevskaia TP; Levitin EI; Mokeeva RA; Faĭnshteĭn FE
    Probl Gematol Pereliv Krovi; 1976 Jul; 21(7):57. PubMed ID: 1071794
    [No Abstract]   [Full Text] [Related]  

  • 90. [Leakadin immunotherapy in the combined therapy of acoustic neurinomas].
    Starchenko AA; Khil'ko VA; Komarets SA; Khlunovskiĭ AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(4):40-2. PubMed ID: 7856375
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
    Griffin JP; Newman RA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Carcinostatic action of 2-cyanaziridines against a sarcoma in rats.
    Bicker U; Fuhse P
    Exp Pathol (Jena); 1975; 10(5-6):279-84. PubMed ID: 1233288
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The influence on the formation of unstable haemoglobin by the immunomodulating 2-cyanaziridines azimexone and BM 41.332 in mice.
    Isert B; Mengel K; Bicker U; Friedberg KD
    J Immunopharmacol; 1985; 7(2):179-93. PubMed ID: 4031509
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Glutathione-conferred resistance to antineoplastics: approaches toward its reduction.
    Somfai-Relle S; Suzukake K; Vistica BP; Vistica DT
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():43-54. PubMed ID: 6733719
    [No Abstract]   [Full Text] [Related]  

  • 95. Experimental investigations on increased resistance to infections with Candida albicans and Staphylococcus aureus Smith by 4-imino-1,4-diazobicyclo-(3.1.0)-hexane-2-on BM 06.002 (prop. INN imexon) in mice.
    Ziegler AE; Bicker U; Hebold G
    Exp Pathol (Jena); 1977; 14(6):321-7. PubMed ID: 598463
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The action of azimexone on the cells of the hemopoietic system in mice, especially after damage with X-rays.
    Friedberg KD; Mengel K; Schlick E
    Radiat Environ Biophys; 1983; 22(2):117-31. PubMed ID: 6611846
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
    Bicker U
    Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531.
    Bicker U; Friedberg KD; Hebold G; Mengel K
    Experientia; 1979 Oct; 35(10):1361-3. PubMed ID: 499423
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
    Peter HH; Dziuba-Traber H; Boerner D
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):353-9. PubMed ID: 6368246
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531.
    Bicker U; Hebold G; Ziegler AE; Maus W
    Exp Pathol (Jena); 1978; 15(1):49-62. PubMed ID: 346364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.